Delving into the Latest Updates on Liquid Thrombin MOCHIDA with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms

Fibrinogenase, トロンビン液モチダソフトボトル 1 万, トロンビン液モチダソフトボトル 5 千

Target

Fibrinogen

Action

stimulants

Mechanism

Fibrinogen stimulants

Therapeutic Areas

Other Diseases

Active Indication

Hemorrhage

Inactive Indication-

Originator Organization

Mochida Pharmaceutical Co., Ltd.

Active Organization

Mochida Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (15 Apr 2003),

Hemorrhage

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 140459322

Source: *****

Sequence Code 57280600

Source: *****

OBJECTIVETo observe the clinical effectiveness of Sanmiao Powder (SP) combined fibrinogenase for injection in treatment of acute deep venous thrombosis (ADVT) of lower limbs.METHODSEighty patients with ADVT were randomly assigned to two groups according to the disease course (within 7 days or 7-28 days), 40 in each group. Every time phase was also divided into two groups, i. e., one group treated with fibrinogenase for injection alone (Group A and C) and another group treated with fibrinogenase for injection + SP administration (Group B and D) , 20 in each group. The clinical effectiveness was observed after 2-week treatment.RESULTSThe fibrinogenase for injection + SP administration showed better effects in alleviating the swelling of limbs, relieving pain, and lowering fibrinogen. Better effects were obtained in the group with the disease course less than 7 days.CONCLUSIONBetter effect on ADVT was obtained by integrative medicine.

100 Deals associated with Liquid Thrombin MOCHIDA

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	Japan	Mochida Pharmaceutical Co., Ltd.	15 Apr 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2018	Not Applicable	Esophageal and Gastric Varices	-	EUS-guided coil embolisation with thrombin injection	ctavbpxrre(jfuhuulawg) = 1 patient died within 3 months of procedure secondary to hepatic decompensation cepigwiebt (ihpozsjyta ) View more	-	01 Oct 2018
EHA2017	Not Applicable	-	-	Fibrinogenase from <em>Adamussium colbecki</em>	(ccbmlnutsr) = jajuujvjoy igccgtuhzo (cysxmwinrb ) View more	-	18 May 2017
EHA2017	Not Applicable	-	-	Control (no fibrinogenase)	(ccbmlnutsr) = kymeizyywc igccgtuhzo (cysxmwinrb ) View more	-	18 May 2017

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data